Home
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $327M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 31.03.2022 | Series C | $100M | - |
| 02.03.2021 | Series A | $113.5M | - |
| 16.12.2020 | Series A | $113.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 04.04.2022 | Neuron23 Closes $100M Series C Financing | Neuron23, a South San Francisco, CA-based biotechnology company, raised $100M in Series C funding. The round, which brought total financing raised to date to $213.5m, was led by SoftBank Vision Fund 2, with participation from Westlake Villa... |
| 31.03.2022 | Neuron23 nabs $100M in SoftBank-led round | Neuron23 has raised a $100 million Series C led by SoftBank's Vision Fund 2. Based in the Bay Area, the company is developing precision medicines for genetically defined neurological and immunological diseases. View round |
| 30.03.2022 | Neuron23 snags $100M and a new Parkinson's disease candidate | Neuron23 has picked a Parkinson’s disease clinical candidate, and, now, the small neurodegenerative-disease-focused biotech will have $100 million more to work with. The young biotech has just completed a series C financing with plans for a... |
| 30.03.2022 | Neuron23 Grabs $100M in Series C | SOUTH SAN FRANCISCO, CA, Neuron23, an early stage biotechnology company, has closed a $100 million Series C financing. >> Click here for more funding data on Neuron23 >> To export Neuron23 funding data to PDF and Excel, clic... |
| 02.03.2021 | Neuron23 closes USD 113.5 million series A and B financing | Martinsried-based Origenis GmbH has announced the formation and funding of South San Francisco biotech company Neuron23 Inc. Neuron23 was launched through a partnership with biotechnology company Origenis with venture capitalist Kleiner Per... |
| 17.12.2020 | Neuron23 emerges from stealth with $113.5M | Neuron23 has announced $33.5 million in Series A funding from WestLake Village BioPartners and Kleiner Perkins, and $80 million in a round led by Redmile Group, with participation from investors including Westlake, Kleiner Perkins, Cowen He... |
| 16.12.2020 | Neuron23 Closes $113.5M Series A and B Financing | Neuron23, Inc., a South San Francisco, CA, and Munich, Germany-based early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, has launched backed by a combi... |
| 16.12.2020 | Neuron23 Snags $113.5M in Series A and B | SOUTH SAN FRANCISCO, CA, Neuron23 today announced its launch backed by a combined $113.5 million Series A and B financing. >> Click here for more funding data on Neuron23 >> To export Neuron23 funding data to PDF and Excel, ... |
| 16.12.2020 | Neuron23 uncloaks with $113.5M to tackle CNS disorders through genetic mutations | Since October 2018, scientists at Neuron23 have worked quietly to find their place in the world of precision medicine. That place is using artificial intelligence and data science to target neurodegenerative and neuroinflammatory diseases i... |
| 16.12.2020 | Neuron23 uncloaks with $113.5M to tackle CNS disorders through genetic mutations | Since October 2018, scientists at Neuron23 have worked quietly to find their place in the world of precision medicine. That place is using artificial intelligence and data science to target neurodegenerative and neuroinflammatory diseases i... |
Show more